Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
5(63%)
Results Posted
150%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
2
25%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Terminated(1)

Detailed Status

Active, not recruiting3
Completed2
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

active_not_recruiting338%
terminated113%
completed225%
recruiting225%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_2

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

NCT05907759
active_not_recruitingphase_1

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097
active_not_recruitingphase_2

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
recruitingphase_2

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
terminatedphase_1

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

NCT03837509
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05907759Phase 2

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Recruiting
NCT05050097Phase 1

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Active Not Recruiting
NCT04270175Phase 2

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active Not Recruiting
NCT06100237Phase 2

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Recruiting
NCT03837509Phase 1

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Terminated
NCT02252172Phase 3

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Completed
NCT04302324Phase 2

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Active Not Recruiting
NCT02195479Phase 3

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8